Saudi Arabia Rheumatoid Arthritis Therapeutics Market Size & Outlook

The rheumatoid arthritis therapeutics market in Saudi Arabia is expected to reach a projected revenue of US$ 215.8 million by 2030. A compound annual growth rate of 4.7% is expected of Saudi Arabia rheumatoid arthritis therapeutics market from 2024 to 2030.
Revenue, 2023 (US$M)
$156.8
Forecast, 2030 (US$M)
$215.8
CAGR, 2024 - 2030
4.7%
Report Coverage
Saudi Arabia

Saudi Arabia rheumatoid arthritis therapeutics market, 2018-2030 (US$M)

Saudi

Related Markets

Saudi Arabia rheumatoid arthritis therapeutics market highlights

  • The Saudi Arabia rheumatoid arthritis therapeutics market generated a revenue of USD 156.8 million in 2023 and is expected to reach USD 215.8 million by 2030.
  • The Saudi Arabia market is expected to grow at a CAGR of 4.7% from 2024 to 2030.
  • In terms of segment, biopharmaceuticals was the largest revenue generating molecule in 2023.
  • Biopharmaceuticals is the most lucrative molecule segment registering the fastest growth during the forecast period.


Rheumatoid arthritis therapeutics market data book summary

Market revenue in 2023USD 156.8 million
Market revenue in 2030USD 215.8 million
Growth rate4.7% (CAGR from 2023 to 2030)
Largest segmentBiopharmaceuticals
Fastest growing segmentBiopharmaceuticals
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPharmaceuticals, Biopharmaceuticals
Key market players worldwideBoehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc


Other key industry trends

  • In terms of revenue, Saudi Arabia accounted for 0.6% of the global rheumatoid arthritis therapeutics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Middle East & Africa, Saudi Arabia rheumatoid arthritis therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 65.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Rheumatoid Arthritis Therapeutics Market Companies

Name Profile # Employees HQ Website

Saudi Arabia rheumatoid arthritis therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.


Biopharmaceuticals was the largest segment with a revenue share of 88.71% in 2023. Horizon Databook has segmented the Saudi Arabia rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.


The Saudi Arabia rheumatoid arthritis therapeutics market has seen key developments, particularly with the approval of new biosimilar drugs. In January 2023, a significant milestone was achieved with the approval of AVT02, a biosimilar for Humira (adalimumab), by the Saudi Food & Drug Authority (SFDA).

This approval came as part of a strategic partnership between Alvotech and Bioventure, marking the first biosimilar to be approved under this collaboration. AVT02, which will be marketed as Simlandi in Saudi Arabia, offers a more cost-effective alternative to Humira and is indicated for the treatment of RA and several other inflammatory diseases.

This approval reflects the growing interest and investment in biosimilars to enhance healthcare access and affordability in the country. Biosimilars such as Simlandi have the potential to expand treatment options for RA patients, providing them with more choices and potentially improving treatment outcomes.

Reasons to subscribe to Saudi Arabia rheumatoid arthritis therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Saudi Arabia rheumatoid arthritis therapeutics market databook

  • Our clientele includes a mix of rheumatoid arthritis therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Saudi Arabia rheumatoid arthritis therapeutics market size, by molecule, 2018-2030 (US$M)

Saudi Arabia Rheumatoid Arthritis Therapeutics Market Share, 2023 & 2030 (US$M)

Saudi Arabia rheumatoid arthritis therapeutics market size, by molecule, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more